Seeking Alpha

JMP Securities says the recent clinical data and enrollment progress of Threshold...

JMP Securities says the recent clinical data and enrollment progress of Threshold Pharmaceuticals' (THLD) TH-302 treatment for soft tissue sarcoma has increased its confidence in the drug's likelihood of success and commercial potential; the firm raises its stock price target to $12 from $7. THLD +7% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs